Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.22), FiscalAI reports.
Bicara Therapeutics Stock Performance
Shares of Bicara Therapeutics stock opened at $8.65 on Monday. The business’s 50 day moving average price is $18.16 and its 200 day moving average price is $20.95. The company has a market cap of $572.40 million, a price-to-earnings ratio of -2.79 and a beta of -0.33. Bicara Therapeutics has a one year low of $7.87 and a one year high of $30.99.
Analyst Ratings Changes
Several analysts recently commented on BCAX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, October 2nd. The Goldman Sachs Group cut shares of Bicara Therapeutics from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $20.00 to $8.00 in a research note on Friday, October 30th. BTIG Research reaffirmed a “buy” rating and set a $39.00 target price on shares of Bicara Therapeutics in a report on Monday, October 19th. Wedbush reduced their target price on shares of Bicara Therapeutics from $33.00 to $24.00 and set an “outperform” rating for the company in a research report on Thursday, October 29th. Finally, BMO Capital Markets initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $35.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $30.91.
View Our Latest Research Report on BCAX
Insider Transactions at Bicara Therapeutics
In other news, CEO Ryan Cohlhepp sold 17,500 shares of Bicara Therapeutics stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total transaction of $400,750.00. Following the transaction, the chief executive officer owned 181,641 shares in the company, valued at $4,159,578.90. The trade was a 8.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.80% of the stock is currently owned by insiders.
About Bicara Therapeutics
Bicara Therapeutics Inc is a clinical-stage biotechnology company developing bifunctional therapies for the treatment of solid tumors. The company’s approach is designed to combine tumor-targeting activity with immune-system modulation in a single therapeutic candidate.
Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. The investigational therapy is designed to target epidermal growth factor receptor (EGFR) on cancer cells while simultaneously trapping transforming growth factor beta (TGF-β), a signaling protein that can contribute to tumor growth and immune suppression.
Featured Stories
- Five stocks we like better than Bicara Therapeutics
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
